Fig. 4From: Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective studyThe spectrum of hotspot mutations in HR-positive breast cancer patients. Each of the 18 hotspot gene mutations has been identified in more than 2 patients listed to the left of the figure. The number of mutations in each gene among the 16 patients is shown (rows). The presence of point mutations, CNVs and both are indicated in red, blue and green, respectivelyBack to article page